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The trimolecular complex comprised of the major
histocompatibility complex, peptide antigen, and the
T cell receptor is a requisite for T cell activation in
normal and autoimmune responses. T cell receptor
analysis is critical to further our understanding
regarding mechanisms of T cell epitope selection
and autoimmune initiation and progression and may
help to identify targets for immunotherapy.
Pemphigus foliaceus is an autoimmune blistering
skin disease characterized by intraepidermal blisters
and circulating autoantibodies directed against des-
moglein 1, a 160 kDa transmembrane desmosomal
molecule expressed in keratinocytes. As tissue dam-
age is mediated by anti-desmoglein 1 antibodies, an
initial T cell response is a likely requirement for
autoantibody generation in this disease. To elucidate
the role of pathogenic T cells in autoimmunity fur-
ther, we have directly characterized the T cell recep-
tor of T cells derived from pemphigus foliaceus
patients. Complementary DNA was isolated from 17
desmoglein 1 speci®c T cell clones generated from
pemphigus foliaceus patients by clonal expansion
in vitro. To analyze the T cell repertoire, a panel of
primers, collectively speci®c for the known human T
cell receptor b variable region (TCRBV) families
were paired with a constant region primer to poly-
merase chain reaction to amplify one distinct T cell
receptor b variable region allele for each T cell clone
studied. Polymerase chain reaction products were
sequenced to determine exact b chain gene usage. In
the 17 clones tested, 10 distinct T cell receptor b
variable region usages and nine T cell receptor b
joining gene segment usages were identi®ed.
Furthermore, T cell receptor b variable region and b
joining usage did not appear to be random, but oli-
goclonal in nature, with some preference shown for
T cell receptor b variable region 5S1 and T cell
receptor BJ2S5. Key words: polymerase chain reaction/
clone cells/receptor/antigen/T-cell/gene rearrangement/
beta-chain T cell antigen receptor/DNA/complementary. J
Invest Dermatol 119:377±383, 2002
P
emphigus foliaceus (PF) is an autoimmune blistering skin
disease that can be broadly subclassi®ed into two types.
Nonendemic PF is found throughout the world,
whereas endemic forms have been found locally in
Brazil, Columbia, and Tunisia (Robledo et al, 1988; Diaz
et al, 1989; Morini et al, 1993; Bastuji-Garin et al, 1995). Endemic
and nonendemic forms are clinically, histologically, and immuno-
logically indistinguishable. Endemic forms are usually diagnosed
based on epidemiology, high frequency of occurrence among
children and young adults, and family history (Squiquera et al,
1988).
Fogo selvagem (FS) is the endemic form of PF found in certain
regions of Brazil. Susceptibility to FS is associated with human
leukocyte antigen (HLA) alleles DRB1*0102, DRB1*0404,
DRB1*1402, and DRB1*1406, with a relative risk as high as 14
for carriers of these alleles (Cerna et al, 1993; Moraes et al, 1997).
Clinically, FS is characterized by highly super®cial, ¯accid skin
blisters. The thin roofs rapidly rupture, giving rise to painful and
crusted erosions with surrounding erythema. Mucous membrane
involvement is rare. Histopathologically, separation in the epider-
mis can be demonstrated just below the corneal layer.
Immunostaining of tissue is characterized by the presence of IgG
autoantibodies, predominantly of the IgG4 subtype. The target of
these autoantibodies has been shown to be desmoglein 1 (Dsg1), a
160 kDa desmosomal cadherin involved in epidermal cell adhesion
(Rock et al, 1989; Wheeler et al, 1991; Buxton et al, 1993).
Whereas the role of anti-Dsg1 autoantibodies in FS has been well
de®ned, little is known about the role of T lymphocytes in disease
onset and progression. It is thought that T helper cell involvement
is required for antibody production by B lymphocytes (Coffman et
al, 1988; Stevens et al, 1988; Hamano et al, 1992). Functionally
relevant T cell epitopes within Dsg1 have not yet been conclusively
de®ned, but are thought to be localized to the extracellular domain
of the protein (Lin et al, 1999).
The ®ne speci®city of T cells for particular major histocompat-
ibility complex±peptide combinations are determined by the
physical shape and biochemical properties of the T cell receptor
(TCR). Structurally, TCR are heterodimers of a and b, or less
commonly g and d chains, which fold into peptide loops
homologous to immunoglobulin complementarity-determining
regions (CDR) encoded by multiple variable (V) regions, joining
(J) regions, and in some cases diversity (D) regions. These gene
segments are clonally rearranged and joined to a constant (C) exon.
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Additional heterogeneity is provided by nucleotide additions at the
recombination sites (N region diversity) (Desiderio et al, 1984).
CDR 1 and 2 are encoded within the V region, whereas the
juncture of the V±D±J region (V±J only in a and g chains) makes
up the CDR3, which forms the center of the antigen binding site
and plays an essential part in antigen recognition (Chothia et al,
1988; Rock et al, 1994). The b chain is thought to play the most
signi®cant part in de®ning the antigen speci®city of T cells,
although the CDR3 region of the a chain does contribute to the
structure of the antigen binding and recognition site (Davis and
Bjorkman, 1988; Jorgensen et al, 1992). A bias in the usage of TCR
gene segments may provide insight into the antigenic epitopes
responsible for autoimmune initiation and propagation and provide
a basis for the development of patient-speci®c therapies.
PF patient-derived T cell clones used in this study have been
previously shown to be Dsg1 speci®c (Lin et al, 1997). To
characterize further the role of pathogenic T cells in PF, we have
directly characterized the TCR of T cells by polymerase chain
reaction (PCR) and nucleotide sequence analysis.
MATERIALS AND METHODS
T cell clones Analysis, derivation, and maintenance of T cell clones
has been described previously (Lin et al, 2000). Brie¯y, peripheral blood
was collected from FS patients and puri®ed by Ficoll-Hypaque density
gradient separation and E-rosetting (Lin et al, 1999). T cell response to
recombinant Dsg1 was determined by T cell proliferation assay as
measured by uptake of [3H]thymidine. Epstein±Barr virus transduced B
lymphocyte cell lines, previously developed from FS patients, were used
as antigen-presenting cells in the maintenance of cell lines and T cell
proliferation assays.
The entire extracellular domain of human Dsg1 was expressed in a
baculovirus expression system as previously described (Amagai et al,
1995). Brie¯y, the appropriate complementary DNA (cDNA) sequences
were isolated by PCR ampli®cation and cloned into the pVL1393
vector. Recombinant viruses were then generated by homologous
recombination according to the manufacturer's instructions (Pharmingen,
San Diego, CA). Recombinant Dsg1 (rDsg1) was produced in Sf9 insect
cell lines and puri®ed using nickel column chromatography (Ding et al,
1999).
T cell proliferation assay T cell responses to rDsg1 or Dsg1-derived
peptides were determined by in vitro assays based on the uptake of
[3H]thymidine as a measurement of proliferation, as previously described
(Lin et al, 1999). Responses to rDsg1 and peptides was expressed as
stimulation index (SI): cpm of cells treated with Dsg1 or peptide per
cpm of cells not treated with antigen. An SI greater than or equal to 3
was considered a positive response.
RNA extraction Total RNA was extracted from stimulated T cell
clones using TRIzol reagent according to the manufacturer's
speci®cations (Life Technologies, Rockville, MD). First-strand cDNA
was synthesized by reverse transcription using Superscript kit following
the manufacturer's protocol (Life Technologies). Complementary DNA
was quantitated using ultraviolet spectrometry, and diluted to 20 ng per
ml with dH20.
PCR ampli®cation of TCR b chains TCR were ampli®ed by PCR
using a 5¢-sense primer speci®c for each of the 24 TCRBV families (and
two subfamilies) and a conserved 3¢-anti-sense TCRBC primer as
previously described (Panzara et al, 1992a, >1992b Longley et al, 1995).
Five microliters (100 ng) of cDNA was combined with 45 ml of reaction
mix containing 1 3 PCR buffer (Life Technologies), 1.5 mM MgCl2,
200 mM deoxyribonucleoside triphosphate, 0.5 mM of the appropriate
TCRBV-speci®c primer, 0.5 mM of TCRBC-speci®c primer, and 1 unit
of Taq DNA polymerase (Life Technologies). Primers were either
synthesized by Life Technologies or kindly provided by Dr J. Longley.
PCR ampli®cation was carried out using 35 cycles of 93°C for 60 s,
55°C for 60 s, and 72°C for 60 s in a DNA thermocycler (Perkin Elmer,
Norwalk, CT). The TCRBV gene usage was identi®ed by the presence
of a single PCR product from the panel of 26 TCRBV±TCRBC primer
reactions.
Cloning and sequencing of PCR-ampli®ed DNA After PCR
ampli®cation and delineation of single TCRBV usage, the TCR b chains
of each clone were reampli®ed for 25 cycles using the same conditions
described above. PCR products were isolated using a PCR puri®cation
kit (Qiagen, Valencia, CA). Fifty nanograms of DNA was adjusted to a
volume of 6 ml, and added to a mixture of 2 ml of 25 ng per ml of
linearized pCR2.1 vector, 1 ml T4 DNA ligase, 1 ml 10 3 ligation
buffer. TA cloning was performed according to the manufacturer's
speci®cations (Invitrogen, Carlsbad, CA). The cloned product was then
transformed into INVaF cells (Invitrogen). Colonies containing inserts
were identi®ed by X-GAL blue±white selection (Life Technologies).
Plasmids containing inserts were puri®ed using plasmid Miniprep kits
(Qiagen), and analyzed by restriction endonuclease digestion for the
presence of proper inserts. Sequencing of cloned inserts was performed at
Rockefeller University Protein/DNA Technology Center using 1000 ng
of template and 4 pmol of M13 reverse primer (5¢-
CAG GAA ACA GCT ATG ACC-3¢). The experimentally elicited
TCRBC, TCRBV, and TCRBJ region sequences were compared to
published human TCR sequences (GenBank).
RESULTS
TCRBV usage TCRBV gene segments expressed by Dsg1-
speci®c T cell clones were examined by PCR ampli®cation using
primers collectively speci®c for the 26 known human subfamilies
(Table I). Collectively, these primers identify the 24 known
TCRBV families. Additionally, subfamilies of TCRBV5
(TCRBV5S1 and TCRBV5S2) and TCRBV13 (TCRBV13S1
and TCRBV13S2) are distinguished by subfamily speci®c primers.
By PCR analysis, we were able to determine preferences for
certain gene segments in 17 T cell clones reactive for the PF
Table I. Sequences of TCRBV and TCRBC speci®c primersa
Family Speci®c primer Family Speci®c primer
TCRBV1 5¢-GCA CAA CAG TTC CCT GAC TTG CAC-3¢ TCRBV13.1 5¢-CAA GGA GAA GTC CCC AAT-3¢
TCRBV2 5¢-TCA TCA ACC ATG CAA GCC TGA CCT-3¢ TCRBV13.2 5¢-GGT GAG GGT ACA ACT GCC-3¢
TCRBV3 5¢-GTC TCT AGA GAG AAG AAG GAG CGC-3¢ TCRBV14 5¢-GTC TCT CGA AAA GAG AAG AGG AAT-3¢
TCRBV4 5¢-ACA TAT GAG AGT GGA TTT GTC ATT-3¢ TCRBV15.1 5¢-AGT GTC TCT CGA CAG GCA CAG GCT-3¢
TCRBV5.1 5¢-ATA CTT CAG TGA GAC ACA GAG AAA C-3¢ TCRBV16 5¢-AAA GAG TCT AAA CAG GAT GAG TCC-3¢
TCRBV5.2±3 5¢-TTC CCT AAC TAT AGC TCT GAG CTG-3¢ TCRBV17 5¢-CAG ATA GTA AAT GAC TTT CAG-3¢
TCRBV6.1±3 5¢-AGG CCT GAG GGA TCC GTC TC-3¢ TCRBV18 5¢-GAT GAG TCA GGA ATG CCA AAG GAA-3¢
TCRBV7 5¢-CCT GAA TGC CCC AAC AGC TCT C-3¢ TCRBV19 5¢-CAA TGC CCC AAG AAC GCA CCC TGC-3¢
TCRBV8 5¢-ATT TAC TTT AAC AAC AAC GTT CCG-3¢ TCRBV20 5¢-AGC TCT GAG GTG CCC CAG AAT CTC-3¢
TCRBV9 5¢-CCT AAA TCT CCA GAC AAA GCT CAC-3¢ TCRBV21 5¢-CCT ATT TCT GGC CAT GCT ACC CT-3¢
TCRBV10 5¢-CTC CAA AAA CTC ATC CTG TAC CTT-3¢ TCRBV22 5¢-GAT CAG AGA AAA GAG GGA AAC-3¢
TCRBV11 5¢-TCA ACA GTC TCC AGA ATA AGG ACG-3¢ TCRBV23 5¢-GAA ATC TCA GAG AAG TCT-3¢
TCRBV12 5¢-AAA GGA GAA GTC TCA GAT-3¢ TCRBV24 5¢-TAC CCA GTT TGG AAG C-3¢
TCRBC 5¢-CTG CTT CTG ATG GCT CAA ACA CAG C-3¢
aThe primers described here are from several different sources: some of these primers were kindly provided by Dr. J. Longley (Longley et al, 1995), whereas others were
synthesized according to previously published sequence data (Panzara et al, 1992a, >b; Longley et al, 1995).
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antigen Dsg1 (Fig 1). Overall, 10 different TCRBV gene segments
were used (Fig 2). Five of 17 T cell clones from two different
patients were found to utilize the same TCRBV gene segmentÐ
TCRBV5S1. No other TCRBV subfamily was expressed more
than twice in this panel of T cell clones. TCRBV13.1, TCRBV20,
and TCRBV23 usage was demonstrated in two clones, in each case
within clones derived from the same patient. TCRBV2, TCRBV3,
TCRBV6.1±3, TCRBV7, TCRBV9, and TCRBV14 usage was
demonstrated in one clone each. The remaining 16 families and
subfamilies were not found to be expressed by any of the T cell
clones tested here.
TCRBJ usage To examine TCR gene usage in more detail, and
to rule out the possibility that T cell clones from the same patient
were derived from the same parental T cells, we sequenced the
PCR products used for full-length TCRBV analysis. In each case,
nucleotide sequencing data con®rmed TCRBV usage as
determined by PCR analysis. In the case of TCRBV6, where the
primer is collectively speci®c for the three known subfamilies
(TCRBV6.1, TCRBV6.2, and TCRBV6.3), we were able to
determine the exact TCRBV usage as TCRBV6.1.
As the 3¢-primer used to amplify the b-chain is speci®c for the
TCRBC region, the resulting product also contains the D and J
regions located between the V and C regions on the b-chain.
TCRBJ usage is summarized in Fig 3 below.
Closer analysis of sequences reveals that clones indeed were not
derived from a common parental T cell; we found differential usage
of TCRBJ gene segments in all cases where identical TCRBV
segments were utilized (Table II). Overall, nine different TCRBJ
gene segments were found to be expressed in the TCR of FS
patient derived T cell clones. TCRBJ2S5 was found in four of 17,
and TCRBJ1S1 was found in three of 17 T cell clones. Three other
gene segments were used twice (TCRBJ1S6, TCRBJ1S2, and
TCRBJ2S3) and four were used once (TCRBJ1S4, TCRBJ1S5,
TCRBJ2S1, and TCRBJ2.7).
Junctional region analysis The junctional region (diversity
region and N-diversity region) was identi®ed by comparing
experimental TCRB sequences to published germline sequences
(GenBank) (Table III). Sequence analysis demonstrated great
diversity in both deduced amino acid sequences and length of the
CDR3 junctional region among 17 clones tested. The length of the
junctional region ranged from 1 to 8 amino acids in size, and there
seemed to be no discernible preference for one size. Amino acid
content (deduced from nucleotide sequence) also did not seem to
follow a pattern.
Functional analysis T cell response to rDsg1 was determined by
proliferation assays. As expected, all 17 rDsg1-speci®c T cell clones
proliferated in response to rDsg1 (see Table II), with SI ranging
from 3.0 to 17.2. The majority of T cell clones (14 of 17) had an SI
Figure 1. PCR-based screen for TCRBV usage. Analysis performed for T cell clone FS12-48 shown here. Each reaction is carried out using
100 ng of cDNA. TCRBV3 is demonstrated here (lane 4 from left). One kilobase ladder shown in lane 1. Actin (M) and actin (M2) are PCR controls
using separate primers and murine cDNA. Actin (H) is a positive control using actin primers and the TCR cDNA. Note: The bright band seen in lane
19 represents a dimer of primers, rather than a true PCR product. To determine its identity, this band was excised from three separate reactions, and
then cloned and sequenced as described above (data not shown). Nucleotide sequencing con®rmed that this band represents dimers of the PCR primers
used for this reaction. Accordingly, it migrates at a size signi®cantly less than 100 bp, which is distinct from the expected size of the TCRBV band
(200±250 bp). The only band representing an ampli®cation of a TCR gene is demonstrated in lane 4, and corresponds to TCRBV3. In addition to TA
cloning mediated sequencing, direct sequencing of the ampli®ed PCR product was performed on one T cell clone (FS12-69) to compare the two
methods of sequencing. Sequences of the ampli®ed TCRB regions were identical for both methods (data not shown).
Figure 3. TCRBJ gene usage. TCRBJ gene
segment usage in 17 Dsg1-speci®c PF T cell
clones. Gene usage was analyzed by nucleotide
sequencing.
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ranging from 3.0 to 4.4; however, FS5-86, FS574, and FS12-82
demonstrated higher proliferative responses (SI of 5.0, 6.9, and
17.2, respectively). There seemed to be no correlation between
intensity of proliferative response and TCRBV and TCRBJ usage.
For example, FS12-69, which uses the same TCRBV±J
combination as FS5-74 was found to proliferate with signi®cantly
less intensity (SI 3.7 vs 6.9).
In an effort to determine the ®ne speci®city of Dsg1 reactive T
cell clones, we tested their proliferative response in vitro to six
synthetic Dsg1-derived peptides, based on epitopes predicted using
an major histocompatibility complex binding motif. (Fridkis-Hareli
et al, 1999) (data not shown). We were able to demonstrate a
speci®c response to one peptide, Dsg1 amino acids 412±426, in
three T cell clones (Table II). Further testing of a more
comprehensive set of overlapping synthetic peptides for epitope
mapping is currently underway.
DISCUSSION
In healthy individuals, the recombination of V (D), J, and C regions
of the TCR is thought to be mostly random, although there is
evidence from monozygotic twin studies that background genes
and HLA haplotype may in¯uence the recombination preferences
of various gene segments (Gulwani-Akolkar et al, 1991; Loveridge
et al, 1991). Germline polymorphisms located within, as well
outside, regions coding for TCR genes (Robinson, 1989; Cornelis
et al, 1993) along with thymic selection (von Boehmer and
Kisielow, 1990) have been shown to contribute to the diversity of
the peripheral TCR repertoire. Changes within germline TCR
sequences may also contribute to autoimmune states in several
ways: (i) exon encoded point mutations could create unique
speci®cities relevant to disease; (ii) a larger complement of TCR
genes could include sequences predisposing to autoimmune disease;
(iii) individuals lacking germline DNA for certain genes could have
a TCR repertoire skewed towards autoimmunity; and (iv)
alterations in regulatory sequences could result in the over-
expression or underexpression of disease relevant TCR.
Not all TCR gene segments are expressed at the same levels in
healthy individuals, and gene usage may be skewed within a given
CD4+ or CD8+ T cell population (Liao et al, 1989; Davey et al,
1991; Akolkar et al, 1993). Gene number at the genomic level has
not been shown to correlate with TCR expression peripherally
Figure 2. TCRBV gene usage. TCRBV gene
segment usage in 17 Dsg1-speci®c PF T cell
clones. Gene usage was analyzed by presence of a
unique PCR product and con®rmed by DNA
sequencing.
Table II. Summary of TCRBV and TCRBJ gene segment usage. HLA typing for patients FS5, FS6, and FS12 was previously
described (Lin et al, 2000) and is listed for each T cell clone derived from a given patienta
T cell clone TCRBV TCRBJ Patient HLA DRB1 HLA DRQ1
Response
to rDSG1
Response
to p412±426
FS12-24 TCRBV23 TCRBJ2S7 FS12 1402/1602 0301/0301 3.8
FS12-38 TCRBV2 TCRBJ2S5 FS12 1402/1602 0301/0301 3.1
FS12-48 TCRBV3 TCRBJ2S1 FS12 1402/1602 0301/0301 3.4 3.8
FS12-58 TCRBV20 TCRBJ1S1 FS12 1402/1602 0301/0301 3.3
FS12-70 TCRBV5S1 TCRBJ2S5 FS12 1402/1602 0301/0301 3.7
FS12-75 TCRBV7 TCRBJ1S4 FS12 1402/1602 0301/0301 3.8
FS12-82 TCRBV23 TCRBJ2S5 FS12 1402/1602 0301/0301 17.2 4.1
FS12-73 TCRBV6S1 TCRBJ1S2 FS12 1402/1602 0301/0301 4.4 3.5
FS12-21 TCRBV14 TCRBJ1S6 FS12 1402/1602 0301/0301 4.1
FS12-69 TCRBV5S1 TCRBJ1S1 FS12 1402/1602 0301/0301 3.7
FS12-74 TCRBV5S1 TCRBJ1S6 FS12 1402/1602 0301/0301 3.2
FS12-84 TCRBV20 TCRBJ2S3 FS12 1402/1602 0301/0301 4.2
FS5-2 TCRBV5S1 TCRBJ2S5 FS5 1406/1602 0301/0301 3.0
FS5-74 TCRBV5S1 TCRBJ1S1 FS5 1406/1602 0301/0301 6.9
FS5-75 TCRBV13S1 TCRBJ1S5 FS5 1406/1602 0301/0301 4.0
FS5-86 TCRBV13S1 TCRBJ1S2 FS5 1406/1602 0301/0301 5.0
FS6-81 TCRBV9 TCRBJ2S3 FS6 1406/1602 0301/0301 3.1
aThe proliferative response of each clone to rDsg1 has been con®rmed and response to peptide Dsg1 412±426 is indicated where applicable (positive response >3). T cell
populations responding to rDsg1 in these three patients were previously characterized (Lin et al, 2000). The responding T cells were found to be CD4+ and CD45RO+,
and proliferative responses were HLA-DR restricted. Cytokine pro®ling indicated that these T cells mount a T helper 2-type response.
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(Robinson, 1992). Robinson (1992) found that several variable
gene segments (TCRBV1, TCRBV2, TCRBV3, and TCRBV4)
were expressed at levels more than twice as high as their germline
gene number should indicate, and that there was a slight preference
for TCRBJ2 families, particularly TCRBJ2S1 and TCRBJ2S7.
Moreover, antigenic history and exposure shape the ®nal expres-
sion of the peripheral T cell repertoire as a dynamic process.
Using primers speci®c for TCRBV gene segment families we
directly analyzed the TCRBV and TCRBJ repertoires of T cells
derived from PF patients. We were able to identify 10 b-chain V
regions and nine b-chain J regions featured at varying frequencies
on the TCR of 17 CD4+/CD45RO+ T helper 2 type T cell clones
from three PF patients. Whereas the selection of TCRBV and
TCRBJ gene segments was not randomly distributed, there was not
exclusive usage of any single TCRBV or TCRBJ segment. Analysis
of the TCR a chain was not performed for this study, but is being
determined in ongoing work. Whereas the a chain may contribute
to the shape of the TCR, major histocompatibility complex±
peptide speci®city appears to be primarily determined by the
CDR3 of the b chain (Davis and Bjorkman, 1988; Jorgensen et al,
1992).
The preference shown for TCRBV5S1 (®ve of 17 clones) and
TCRBJ2S5 (four of 17) may have several implications for the role
of the TCR in the initiation of an autoimmune state in PF. It is
important to note that, whereas two clones (FS5-2 and FS12-70)
from different patients were found to contain the combination
TCRBV5S1±BJ2S5, there did not seem to be an overall preference
for this particular TCRBV±J combination. In fact, three other
instances of TCRBV5S1 usage and two other instances of
TCRBJ2S5 usage were found in conjunction with other TCRBJ
and TCRBV gene segments, respectively. Duplicate usage of the
TCRBV5S1±BJ1S1 combination in two T cell clones from
different patients (FS12-69 and FS5-74) represents the only other
multiple usage of a particular TCRBV±BJ combination. Curiously,
for each instance of usage of an identical TCRBV±J combination,
one clone each from patient FS5 and FS12 was included. These
two patients each carry a different HLA allele thought to be
associated with PF; patient FS5 types as HLA DRB1*1406,
whereas patient FS12 carries HLA DRB1*1402 (Cerna et al, 1993;
Moraes et al, 1997). The observation that two patients with
different disease susceptibility HLA alleles have autoreactive T cells
with identical TCRBV±J gene usage certainly hints at a preferential
usage of certain gene segment combinations in PF. These ®ndings
will need to be examined in a larger data set of patients and/or
clones to draw signi®cant conclusions.
Close examination of the CDR3 junctional region (see
Table III for detail) reveals startling heterogeneity. There seems
to be no discernible pattern in either length or amino acid
preferences in this region. Between 1 and 8 amino acids (deduced
from nucleotide sequence) were found to make up this region.
Clearly, there does not seem to be a strong selection in favor of a
particular amino acid(s).
Overall, TCRBV and TCRBJ analysis indicates that TCR gene
usage in PF shows preferences, but is not completely restricted to a
given gene family. Instead, we demonstrate oligoclonality.
Moreover, TCR gene usage varies within a given patient,
indicating that disease induction and/or progression is not
dependent on only one set of TCR gene segments.
A number of investigators have studied TCR gene segment
usage in murine models of autoimmune diseases. Nearly mono-
Table III. Sequence alignment and length variability of CDR3 regiona
Clone TCRBV Junctional region TCRBJ
FS12-24 TCRBV23Ð¼CASS G N R G L G EQYFGPGTRLTVT¼±TCRBJ2S7
GGAAATCGGGGTTTGGGC
FS12-38 TCRBV2Ð¼FYIC S A A V A G E ETQYFGPGTRLLVL¼±TCRBJ2S5
AGTGCGGCGGTAGCGGGGGAA
FS12-48 TCRBV3Ð¼CASS S T K R G H EQFFGPGTRLTVL¼±TCRBJ2S1
TCGACCAAAAGGGGGCAT
FS12-58 TCRBV20- CASS S R N G TEAFFGQGTRLTVV¼±TCRBJ1S1
AGCCGGAATGGC
FS12-69 TCRBV5S1Ð¼CASS A G S W K EAFFGQGTRLTVV¼±TCRBJ1S1
GCTGGCAGCTGGAAG
FS12-70 TCRBV5S1Ð¼CASG V T L S T G ETQYFGTRLLVL¼±TCRBJ2S5
GTAACACTCTCCACCGGT
FS12-75 TCRBV7Ð¼CASS R S A T G R S A TNEKLFFGSGTNLSV ¼±TCRBJ1S4
CGCAGCGCGACAGGGAGGTCCGCA
FS12-82 TCRBV23Ð¼CAST T K ETQYFGTRLLVL¼±TCRBJ2S5
ACCAAA
FS12-73 TCRBV6S1Ð¼CASS W T A G Q G S GYTFGSGTRLTVV¼±TCRBJ1S2
TGGACCGCCGGACAGGGGTCT
FS12-21 TCRBV14Ð¼CASS V S G T V NSPLHFGNGTRLTVT¼±TCRBJ1S6
GTATCCGGGACCGTT
FS12-74 TCRBV5S1Ð¼CASS F N R D S A A R SPLHFGNGTRLTVT¼±TCRBJ1S6
TTCAACAGGGATTCTGCGGCTCGA
FS12-84 TCRBV20Ð¼CAWS V R N TQYFGPGTRLTVL¼±TCRBJ2S3
GTAAGAAAT
FS5-2 TCRBV5S1Ð¼CASS L QETQYFGPGTRLLVL¼±TCRBJ2S5
CTA
FS5-74 TCRBV5S1Ð¼CASS L G D TEAFFGQGTRLTVV¼±TCRBJ1S1
TTGGGGGAC
FS5-75 TCRBV13S1Ð¼CASS T S R G R G QPQHFGDGTRLSIL¼±TCRBJ1S5
TACTCGCGGGGTAGGGGT
FS5-86 TCRBV13S1Ð¼CASS A A R W GYTFGSGTRLTVV¼±TCRBJ1S2
GCTGCCAGGTGG
FS6-81 TCRBV9Ð¼CASS R L A G Q M DTQYFGPGTRLTVL¼±TCRBJ2S3
CGACTAGCGGGTCAGATG
aAmino acid sequence is deduced from nucleic acid sequence information. The boundaries of TCRBV and TCRBJ regions were determined by comparison with publicly
available germline sequences (GenBank).
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clonal usage of TCRB8S2 and TCRBJ2S5 gene segments was
shown in encephalitogen-speci®c T cells in the (PL/J) mouse
model of experimental autoimmune encephalomyelitis (Acha-
Orbea et al, 1988; Zamvil et al, 1988). Similarly, TCRBV8S1 and
TCRBV8S2 were also found in 60% of T cells isolated from
enlarged lymph nodes of MRL-lpr/lpr lupus mice (Singer et al,
1986). TCRBV8S2, TCRBV10, and TCRBV12 were found to be
oligoclonally expressed throughout disease initiation and progres-
sion of experimental autoimmune myocarditis (Matsumoto et al,
2000).
Analysis of human diseases has shown greater diversity, fre-
quently showing oligoclonal selection, but rarely monoclonal gene
usage. It has been shown that, whereas there seems to be a
preference for TCRBV8S2 in multiple sclerosis lesions, there is
multiple TCRBV and TCRBJ gene segment usage seen overall
(Oksenberg et al, 1993; Lodge et al, 1994). An early study of TCR
gene diversity of peripheral blood T cells and lesional skin in
psoriasis showed no skewing of the repertoire towards a particular
set of V-region genes (Moss et al, 1997); however, Vekony et al
(1997) demonstrated a slight preference for TCRBV2 and
TCRBV6 in early psoriatic lesions, whereas Chang et al (1994)
reported increased usage of TCRBV3S1 and TCRBV13S1 in
CD8+ cells found in active lesions. Similar evidence of some
oligoclonal preference has been reported in systemic lupus
erythematosus (Holbrook et al, 1996), alopecia areata
(TCRBV5S2, TCRBV14, TCRBV22) (Szafer et al, 1995), and
rheumatoid arthritis (TCRBV12, TCRBV3, TCRBV14,
TCRBV17) (Howell et al, 1991; DerSimonian et al, 1993; Hall et
al, 1998). Functional relevance remains to be established in each
case. Similarly, it is dif®cult at this point to assess whether our
demonstration of oligoclonal TCRBV and TCRBJ preference in PF
T cell clones is relevant for disease induction or re¯ects T cell
speci®cities generated as a result of epitope spreading at a point
further along in disease progression.
In an effort to determine whether there is a correlation between
epitope-speci®c response and TCRBV gene usage, we tested
patient-derived T cell clones for proliferative responses to several
Dsg1-derived synthetic peptides. We identi®ed a 15 amino acid
peptide (Dsg1 amino acids 412±426), which elicited a response in
three T cell clones tested (FS12-48, FS12-82, and FS12-73).
Interestingly, none of these three T cell clones show duplicate
usage of either TCRBV or TCRBJ gene segments. There also
seemed to be no discernible pattern in the amino acid content of
the junctional region. These ®ndings are relevant for the prospect
of TCRBV (or other gene segment) speci®c immunotherapy. The
possibility of multiple TCR subspeci®cities capable of recognizing
even a single relevant epitope suggests that it will be dif®cult to
easily target the complement of autoreactive T cells in a given
disease.
Still, recent advances in immunotherapy highlight the thera-
peutic prospects based on precisely identifying the TCR involved
in autoimmune disease. Treatment with a peptide speci®c for the
TCRBV region (Acha-Orbea et al, 1988; Urban et al, 1988), or
vaccination with synthetic peptides based on particular TCRBV
region sequences (Howell et al, 1989; Vandenbark et al, 1989;
Offner et al, 1991) have been shown to be effective in
downregulating the immune response in experimental autoimmune
encephalomyelitis. More recently, clinical human trials in rheuma-
toid arthritis using peptides based on TCRBV3, TCRBV14, and
TCRBV17 have shown that such vaccinations may be effective in
the prevention of human disease. Similarly, trials using a TCRBV6
CDR3 region peptide vaccine in patients with multiple sclerosis
have also shown promising results (Gold et al, 1997). Vaccination
with DNA coding for disease-related TCRBV gene segments have
also shown promise in experimental autoimmune encephalomye-
litis (TCRBV8.2) (Waisman et al, 1996) and experimental
autoimmune myocarditis (TCRBV8.2 and TCRBV10)
(Matsumoto et al, 2000).
A major goal of characterizing T cell speci®cities in auto-
immunity is to understand the molecular events that lead to
autoimmune disease initiation and propagation. A critical link in
this chain of events is the speci®city of the TCR for a given
antigenic epitope. Whereas the analysis of T cell clone TCR usage
may provide important insights into the events that govern the
molecular interactions of the trimolecular complex, it is limited by
the fact that it can only re¯ect a narrow snapshot of a patient's
entire T cell complement and provides only indirect evidence of
antigen speci®city. The dif®culty of deriving and maintaining T cell
clones effectively renders this approach impractical for screening
larger patient populations or a comprehensive sample of T cells.
TCR spectratyping aims to identify gene usage on a broader scale
in peripheral blood and tissue, yet fails to provide information on
antigen-speci®c interactions. Recent advances in T cell analysis are
aimed to improve the sensitivity and accuracy of determining T cell
activation and speci®city. Flow cytometric assessment of intra-
cellular cytokine release can be used to detect antigen-speci®c T
cells following stimulation with protein antigens (Waldrop et al,
1997) or even peptides (Kern et al, 1998). Fluorescently labeled
tetrameric major histocompatibility complex±peptide complexes
are increasingly being used to determine directly and more
accurately the number of peripheral antigen-speci®c T cells in
HLA class I and class II systems (Altman et al, 1996; Novak et al,
1999; Kwok et al, 2000). To advance our understanding of the role
of T cells in autoimmune disease, future work will need to
incorporate sequence and structural detail with large-scale analysis
of the TCR ®ne speci®city and functional activity.
We would like to thanks Dr. J. Longley for kindly providing some of the primers
used in this experiment and technical assistance.
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